

Resource Summary Report

Generated by [ASWG](#) on Aug 2, 2026

Oncotator

RRID:SCR_005183

Type: Tool

Proper Citation

Oncotator (RRID:SCR_005183)

Resource Information

URL: <http://www.broadinstitute.org/cancer/cga/ncotator>

Proper Citation: Oncotator (RRID:SCR_005183)

Description: A tool for annotating human genomic point mutations and indels with data relevant to cancer researchers. Genomic Annotations, Protein Annotations, and Cancer Annotations are aggregated from many resources. A standalone version of Oncotator is being developed.

Abbreviations: Oncotator

Resource Type: data analysis service, service resource, production service resource, analysis service resource

Keywords: annotate, genomic, point mutation, indel, mutation, genome, protein, variant

Related Condition: Cancer

Resource Name: Oncotator

Resource ID: SCR_005183

Alternate IDs: OMICS_00178

Record Creation Time: 20220129T080228+0000

Record Last Update: 20260801T190925+0000

Ratings and Alerts

No rating or validation information has been found for Oncotator.

No alerts have been found for Oncotator.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 215 mentions in open access literature.

Listed below are recent publications. The full list is available at [ASWG](#).

Oh SY, et al. (2025) The potential of lazertinib and amivantamab combination therapy as a treatment strategy for uncommon EGFR-mutated NSCLC. *Cell reports. Medicine*, 6(2), 101929.

Ghosh A, et al. (2025) Genomic hallmarks of endocrine therapy resistance in ER/PR+HER2- breast tumours. *Communications biology*, 8(1), 207.

Zhang X, et al. (2025) Comprehensive molecular profiling of FH-deficient renal cell carcinoma identifies molecular subtypes and potential therapeutic targets. *Nature communications*, 16(1), 4398.

Kübler K, et al. (2025) Tamoxifen induces PI3K activation in uterine cancer. *Nature genetics*, 57(9), 2192.

Zhong S, et al. (2025) Genomic landscape and immunological profile of glioblastoma in East Asian patients. *Cell reports. Medicine*, 6(8), 102217.

Liu Z, et al. (2025) Illuminating the FGFR fusion landscape in Chinese patients: unveiling novel molecular insights and clinical implications. *The oncologist*, 30(11).

Yang Q, et al. (2025) Combined utility of genomic breakpoints and frame is a reliable predictor of ALK transcript function. *Scientific reports*, 15(1), 8437.

Feng EM, et al. (2025) Racial variation in the advanced prostate cancer genome. *Prostate cancer and prostatic diseases*, 28(4), 902.

Wu M, et al. (2025) Genomic copy-number variants drive apoptotic evasion underlying acquired resistance to immune checkpoint inhibitors. *Immunity*, 58(11), 2864.

Sun W, et al. (2025) A mutational process signature and genomic alterations associated with outcome and immunogenicity in cancers with brain metastasis. *Frontiers in immunology*, 16, 1607772.

Wang H, et al. (2025) Genome-Wide Association Analysis of Flavor Precursor Traits in Chengkou Mountain Chicken. *Animals : an open access journal from MDPI*, 15(12).

Lu S, et al. (2025) Safety and feasibility of anlotinib in children with high risk, recurrent or refractory sarcomas: an open-label, single-centre, single-arm, phase Ia/Ib trial. *EClinicalMedicine*, 84, 103258.

Knight AD, et al. (2025) Melanoma to rhabdomyosarcoma plasticity in the setting of immunotherapy. medRxiv : the preprint server for health sciences.

Liu X, et al. (2024) Tumor phylogeography reveals block-shaped spatial heterogeneity and the mode of evolution in Hepatocellular Carcinoma. Nature communications, 15(1), 3169.

Zhang J, et al. (2024) Tet methylcytosine dioxygenase 2 (TET2) deficiency elicits EGFR-TKI (tyrosine kinase inhibitors) resistance in non-small cell lung cancer. Signal transduction and targeted therapy, 9(1), 65.

Díaz-Gay M, et al. (2024) The mutagenic forces shaping the genomic landscape of lung cancer in never smokers. medRxiv : the preprint server for health sciences.

Chang Y, et al. (2024) CapHLA: a comprehensive tool to predict peptide presentation and binding to HLA class I and class II. Briefings in bioinformatics, 26(1).

Zou H, et al. (2024) Dynamic monitoring of circulating tumor DNA reveals outcomes and genomic alterations in patients with relapsed or refractory large B-cell lymphoma undergoing CAR T-cell therapy. Journal for immunotherapy of cancer, 12(3).

Choudhury AD, et al. (2024) Randomized Phase II Study Evaluating the Addition of Pembrolizumab to Radium-223 in Metastatic Castration-resistant Prostate Cancer. Cancer immunology research, 12(6), 704.

Czerniak B, et al. (2024) Inferring Bladder Cancer Evolution from Mucosal field Effects by Whole-Organ Spatial Mutational, Proteomic, and Metabolomic Mapping. Research square.